Intensive chemotherapy is one way of treating acute myeloid leukemia (AML), but many older adults cannot tolerate the side effects of this approach. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called sapacitabine in patients age 70 and older who are newly diagnosed with AML.
Sapacitabine kills cancer cells by causing breaks in their DNA (genetic material). It is a capsule that is taken orally (by mouth). It will be compared in this study to decitabine, which has been used for many years to treat older people with acute leukemia. Decitabine is given intravenously (by vein).
Patients in this study will be randomly assigned to receive either sapacitabine or decitabine.